Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply

Abstract

LINKED CONTENT This article is linked to Hatanaka et al papers. To view these articles, visit https://doi.org/10.1111/apt.18237 and https://doi.org/10.1111/apt.18296.